ErbB signaling pathway； HIF-1 signaling pathway；Cell cycle； Melanoma；p53 signaling pathway；PI3K-Akt signaling pathway；Viral carcinogenesis；Hepatitis C；Hepatitis B；HTLV-I infection；Epstein-Barr virus infection；Chronic myeloid leukemia；Pathways in cancer；Proteoglycans in cancer；Transcriptional misregulation in cancer；Prostate cancer；Bladder cancer；Glioma

For instance, through its miRNA response elements (MREs) to compete for miR-106a-5p, lncRNA-FER1L4 regulates the expression of PTEN, RB1, RUNX1, VEGFA, CDKN1A, E2F1, HIPK3, IL-10, and PAK7.

Long noncoding RNA associated-competing endogenous RNAs in gastric cancer PTENP1 Functions as a Competing Endogenous RNA (ceRNA) to Regulate PTEN Expression by Sponging miR-499-5p.

ErbB signaling pathway；HIF-1 signaling pathway；Cell cycle；p53 signaling pathway；PI3K-Akt signaling pathway；Hepatitis C；Hepatitis B；Bladder cancer；Chronic myeloid leukemia；Melanoma；HTLV-I infection；Glioma；Epstein-Barr virus infection；Pathways in cancer；Transcriptional misregulation in cancer；Prostate cancer；Viral carcinogenesis；Proteoglycans in cancer

Mechanistically, we demonstrated that circ-ITCH up-regulates the expression of miR-17 and miR-224 target gene p21 and PTEN through 'sponging' miR-17 and miR-224, which suppressed the aggressive biological behaviors of BCa.

Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression.

ErbB signaling pathway；HIF-1 signaling pathway；Cell cycle；p53 signaling pathway；PI3K-Akt signaling pathway；Hepatitis C；Hepatitis B；Bladder cancer；Chronic myeloid leukemia；Melanoma；HTLV-I infection；Glioma；Epstein-Barr virus infection；Pathways in cancer；Transcriptional misregulation in cancer；Prostate cancer；Viral carcinogenesis；Proteoglycans in cancer

circMTO1 suppresses HCC progression by acting as the sponge of oncogenic miR-9 to promote p21 expression, suggesting that circMTO1 is a potential target in HCC treatment.

circMTO1 suppresses HCC progression by acting as the sponge of oncogenic miR-9 to promote p21 expression, suggesting that circMTO1 is a potential target in HCC treatment.